title: [In vivo bioequivalence study of Sulpirid (GYKI-Alkaloida) and Dogmatil fort (Delagrange) 200 mg sulpiride tablets in healthy volunteers].
abstract: A single-dose, "crossover" bioequivalence study was conducted in healthy volunteers by comparing sulpiride serum levels after oral administration of the Test Product Sulpiride (200 mg) (GYKI-Alkaloida) in fasting subjects with those produced after oral administration of a marketed reference product (200 mg) (Delagrange Co., France). Statistical comparisons of Cmax, Tmax and AUC0-infinity have been performed utilizing ANOVA with subject, group, subject within group, period and product as sources of variance. No significant differences between the Test Drug and the Reference Drug considering the pharmacokinetic parameters Cmax, Tmax and AUC0-infinity were found. The 95% confidence intervals were as follows: AUC0-infinity: -20.46% and 31.19%, Cmax: -28.05% and 26.65% and Tmax: -43.53% and 20.67%. In the study for the analysis of Sulpiride a specific HPLC procedure with uv detection (lambda = 228 nm) and an internal standard were applied according to P. Nicolas et al. with modification. Sulpiride levels in serum reached a maximum at 4.4 hr +/- 1.5 (S.D.) following administration of Sulpiride tablet and at 5.0 hr +/- 0.8 (S.D.) after Dogmatil fort tablet. The maximal serum concentrations were 506.1 ng/ml +/- 87.2 (S.D.) and 509.1 ng/ml +/- 101.9 (S.D.) for Sulpiride and Dogmatil fort, respectively. The half-life of Sulpiride in serum was 9.9 hr +/- 1.3 (S.D.) following dosing with Dogmatil fort tablet and 12.2 hr +/- 3.0 (S.D.) following dosing with Sulpiride tablet.
authors.affiliation: Gyógyszerkutató Intézet Kv. Budapest.
authors.forename: L
authors.initials: L
authors.lastname: Tomori
authors.forename: L
authors.initials: L
authors.lastname: Vereczkey
authors.forename: T
authors.initials: T
authors.lastname: Past
authors.forename: J
authors.initials: J
authors.lastname: Singer
authors.forename: S
authors.initials: S
authors.lastname: Mészáros
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D006801:Humans; D012016:Reference Values; D013469:Sulpiride / Q000493:pharmacokinetics*; D013607:Tablets; D013810:Therapeutic Equivalency
chemical_list: D013607:Tablets; D013469:Sulpiride
vernacular_title: A Sulpirid (GYKI-Alkaloida) és a Dogmatil fort (Delagrange) 200 mg sulpirid hatóanyagtartalmú tabletták in vivo bioekvivalencia vizsgálata egészséges önkénteseken.